Metformin does not directly damage nerves, but long-term use can cause neuropathy indirectly by lowering vitamin B12. Roughly 6 to 30 percent of long-term users develop B12 deficiency, depending on dose and duration, and B12 deficiency is a well-established cause of peripheral neuropathy. So the honest answer is yes, metformin can contribute to neuropathy, but through a nutritional mechanism rather than a toxic one. This distinction matters because B12-related nerve damage is often reversible when caught early, while diabetic neuropathy from high blood sugar is usually progressive.
The mechanism: how metformin lowers vitamin B12
Metformin interferes with calcium-dependent binding of the B12-intrinsic factor complex at the ileum receptor. In plain terms: B12 needs calcium to dock onto the receptor that pulls it into the bloodstream, and metformin disrupts that calcium signaling. The result is reduced absorption of B12 from food and from supplements, even when intake looks adequate.
This is a slow, cumulative effect. It typically takes years of consistent use to deplete liver stores enough to produce symptoms. The mechanism is dose-dependent and duration-dependent, which is why a person on 500 mg daily for two years faces a very different risk than someone on 2,000 mg daily for ten years.
There is also a second pathway under investigation. Some researchers propose that metformin may affect nerve function through altered gut microbiome composition or mild effects on mitochondrial function. This remains hypothesis, not established fact. The B12 pathway is the one with consistent human evidence behind it.
How common is B12 deficiency on metformin?
The numbers vary widely by population and definition of deficiency. A commonly cited figure is that 6 to 30 percent of patients on long-term metformin develop biochemical B12 deficiency, per a 2016 review in the Journal of Clinical Endocrinology and Metabolism. Clinical deficiency with symptoms is less common, but still meaningfully elevated compared to non-users.
| Factor | Lower risk | Higher risk |
|---|---|---|
| Daily dose | 500 mg | 2,000 mg or more |
| Duration of use | Under 2 years | Over 4 years |
| Baseline B12 status | Normal, meat-rich diet | Low-normal or vegan diet |
| Age | Under 50 | Over 60 |
| Other B12 stressors | None | PPIs, gastric surgery, alcohol use |
| Metformin formulation | Immediate release, low dose | Extended release, high dose |
The dose-response relationship is the strongest signal. Patients taking more than 1,500 mg daily for more than four years show the highest rates of deficiency in most cohort studies.
Why this gets confused with diabetic neuropathy
Type 2 diabetes itself causes peripheral neuropathy in roughly 50 percent of patients over time, driven by chronic hyperglycemia, microvascular damage, and oxidative stress. Because metformin is prescribed for diabetes, any neuropathy in a metformin user is often assumed to be diabetic neuropathy by default. That assumption is the central misconception this article addresses.
The two conditions can look nearly identical on exam: symmetric stocking-glove numbness, burning, tingling, and loss of vibration sense. The difference is in the trajectory and the reversibility. Diabetic neuropathy tends to progress steadily and is largely irreversible once established. B12-deficiency neuropathy can plateau or improve substantially with repletion, especially if treated within the first year of symptoms.
A 2019 study in the journal Diabetes Care found that metformin users with neuropathy had significantly lower B12 levels than metformin users without neuropathy, independent of glycemic control. That finding does not prove causation, but it supports screening.
The timeline: when B12 neuropathy appears in metformin users
| Time on metformin | What is happening | Typical B12 level | Symptoms |
|---|---|---|---|
| 0 to 6 months | Liver stores still full | Normal (200 to 900 pg/mL) | None |
| 6 to 24 months | Gradual depletion begins | Low-normal (200 to 300 pg/mL) | Usually none |
| 2 to 4 years | Stores depleted in vulnerable patients | Borderline (150 to 200 pg/mL) | Occasional fatigue, mild tingling |
| 4 to 6 years | Overt deficiency in high-risk groups | Low (under 150 pg/mL) | Numbness, burning feet, balance issues |
| 6 to 10 years | Cumulative risk highest | Low to very low | Established sensory neuropathy |
| After 10 years | Risk plateaus but persists | Variable | May be irreversible if untreated |
This table reflects typical patterns, not guarantees. Some patients develop deficiency within two years, especially if they have low dietary intake or take proton pump inhibitors concurrently. Others never develop it despite decades of use.
The numbers that change screening decisions
The standard serum B12 cutoff is 200 pg/mL, but that threshold misses many deficient patients. Symptoms can appear at levels between 200 and 300 pg/mL, a range often labeled "borderline." For this reason, the American Diabetes Association recommends periodic B12 measurement in patients on long-term metformin, particularly those with anemia or neuropathy, per its 2023 Standards of Care.
Methylmalonic acid and homocysteine are more sensitive markers. They rise when tissue B12 is insufficient even if serum B12 reads normal. A patient with a serum B12 of 250 pg/mL but an elevated methylmalonic acid above 0.4 micromol/L likely has functional deficiency. These secondary tests cost more, typically USD 30 to USD 60 each in the US, but they resolve ambiguous cases that serum B12 alone cannot.
Reconciling the thresholds: serum B12 under 200 pg/mL is definite deficiency, 200 to 300 pg/mL is indeterminate and warrants secondary testing, and above 300 pg/mL with normal methylmalonic acid effectively rules out deficiency.
Red flags that mean see a doctor now
Most B12-related neuropathy develops slowly and is not an emergency. Certain features, however, require prompt evaluation because they suggest a different or more dangerous cause.
- Rapidly progressive weakness, especially ascending from the feet
- Asymmetric or focal numbness rather than the typical symmetric pattern
- New bowel or bladder dysfunction alongside leg symptoms
- Severe unsteadiness or falls
- Symptoms accompanied by unexplained weight loss
- Visual changes or cognitive decline
These do not fit the slow B12-deficiency pattern and should not be attributed to metformin without investigation.
What to actually do
If you take metformin and have any numbness, tingling, or burning in your feet or hands, the practical steps are concrete.
Ask for a serum B12 level, and if it is between 200 and 300 pg/mL, request methylmalonic acid and homocysteine. Do not accept a "normal" B12 result as the end of the conversation if you have symptoms.
Do not stop metformin on your own. It remains a first-line, well-validated therapy for type 2 diabetes with strong cardiovascular and glycemic benefits. The solution to B12 deficiency is repletion, not discontinuation.
Oral B12 supplementation at 1,000 to 2,000 micrograms daily is usually sufficient even with impaired absorption, because a small fraction is absorbed passively without intrinsic factor. Severe deficiency with neurological symptoms may warrant intramuscular injections of 1,000 micrograms weekly for several weeks, followed by maintenance dosing.
Recheck B12 levels every 6 to 12 months if you remain on metformin, or annually at minimum. If you take a proton pump inhibitor or have had gastric surgery, screen more often, since those factors compound the absorption problem.
Address the underlying diabetes control as well. Good glycemic control reduces the risk of diabetic neuropathy, which is far more common than B12-related neuropathy in this population.
When neuropathy is not from metformin at all
It is important to be clear about what the evidence does and does not show. No large randomized trial has demonstrated that metformin causes neuropathy through a non-B12 mechanism. The association is real at the population level, but it is mediated by B12 status.
Some patients on metformin with normal B12 still develop neuropathy. In those cases, the cause is almost always the diabetes itself, or another condition such as alcohol use, thyroid disease, kidney disease, or a hereditary neuropathy. Attributing all neuropathy in metformin users to the drug would be a mistake and could delay treatment of the actual cause.
There is also a counterintuitive point worth stating plainly. Metformin's benefits for cardiovascular risk and glycemic control are large and well-established. For most patients, the small absolute risk of B12 deficiency is manageable with monitoring, and the drug should not be avoided out of fear of neuropathy. The risk is real but modifiable, which is very different from the risk being unacceptable.
The bottom line is that metformin can contribute to neuropathy by lowering B12, that this is detectable with simple blood tests, and that it is usually reversible when caught early. The patients who do worst are those whose symptoms are written off as inevitable diabetic neuropathy without a B12 check. A single blood draw can change that trajectory.